Upstream Manufacturing

INSIGHTS ON UPSTREAM MANUFACTURING

In Vivo Manufacturing: When The Body Becomes The Bioreactor
Breakthrough therapies are reshaping medicine, but manufacturing complexity is holding them back. Discover how rethinking production and delivery could expand reach and improve patient experience.
The Body As A Bioreactor – The Vision
As cell therapy manufacturing reaches its limits, a new model is emerging. Learn how in vivo approaches that harness the body as a bioreactor could expand access and reshape the future.
Enabling A Four-Fold Increase In Titer For mAb Manufacturing
A platform-based upstream strategy increased monoclonal antibody titers fourfold, improving yield, efficiency, and scalability via optimized clones, process design, and rapid scale-up.
Unlock The Potential Of GPEx® Lightning: Accelerate Your HEK Cell Line Development
Cut HEK cell line development to four months with 30% higher titers. GPEx® Lightning delivers faster, scalable biologics manufacturing. Access the full summary now.

Comprehensive Bioprocess Control: Substrate, Metabolite And Product Analysis
5/6/2026

Explore how multi-parameter bioprocess analyzers support monitoring of 30+ bioprocess parameters across mammalian and microbial systems to optimize yield and product quality.
Rapid Selection Of High-Performance CHO Basal And Feed Media
5/5/2026

A CHO-S bispecific antibody program needed a better basal and feed media combination. Learn how the screening of 180 conditions in 12 weeks identified one that delivered 38% higher titers.
Aligning Upstream And Downstream Development (Part 2)
5/5/2026

In Part 2 of this conversation on “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their discussion about how upstream and downstream development teams can work together to accelerate timelines and reduce risk and bottlenecks in process development.
Top 5 Barriers To Scalable ncAA Conjugation And What's Finally Changing
5/5/2026

Examine data from an anti-GPCR VHH program that shows how ncAA conjugation barriers, like yield loss, toxicity, incomplete incorporation, can be overcome at scale.

A Data Driven Approach To Mammalian Scale-Up And Transfer

Mammalian scale‑up is vulnerable to subtle changes. Discover a mechanistic, data‑driven approach that uses cellular kinetics, modeling, and scaled‑down validation to help reduce transfer risk.
Raising The Bar On What's Achievable In Continuous Manufacturing

Integrated perfusion and downstream processing reduce timelines without compromising quality, showing how continuous manufacturing is elevating yield, efficiency, and long-term stability.
Meet MaruXTM: Setting The Standard For End-To-End Continuous Biomanufacturing

Continuous biomanufacturing boosts speed, flexibility, and control. Modular automation, intensified processing, and streamlined workflows drive productivity and consistent quality.
Cell Therapy Selection Guide: Connected From Activation To Expansion

Active bead release gives manufacturers precise control over T cell isolation timing, phenotype preservation, and workflow efficiency, eliminating multi-day passive dissociation delays.
Integrated T Cell Activation: Soluble DynActivator CD3/CD28 Prototype

Bead-free T cell activation is now achievable with a soluble, GMP-compliant format that supports up to 1.5 billion cells per vial, decouples activation from isolation, and removes with a simple cell wash.